Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer
Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved overall survival for patients ...
Jun 1, 2026
0
4









